H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Bicara Therapeutics (BCAX) to $40 from $41 and keeps a Buy rating on the shares following the Q2 report. The firm is factoring in higher long-term operating expenses.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Bicara Therapeutics initiated with an Overweight at Piper Sandler
- Bicara Therapeutics Reports Q2 2025 Results and Progress
- Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
- Bicara Therapeutics reports Q2 EPS (50c), consensus (54c)
- Bicara Therapeutics expects cash to fund operations into 1H of 2029